Last reviewed · How we verify
NCT04986683
Diffusion MRI Methods to Minimize Postoperative Deficits in Pediatric Epilepsy Surgery
NA trial testing Brain magnetic resonance imaging in Focal Epilepsy in 60 participants. Currently enrolling.
30 June 2026
Quick facts
| Lead sponsor | Wayne State University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 60 |
| Start date | 1 August 2021 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Brain magnetic resonance imaging
- Neuro-psychology testing
Conditions studied
- Focal Epilepsy — all drugs for Focal Epilepsy →
Sponsor
Wayne State University
Who can join
Adults 3 to 19, any sex, with Focal Epilepsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project will test the accuracy of a novel diffusion-weighted magnetic resonance imaging (DWMRI) approach using a deep convolutional neural network (DCNN) to predict an optimal resection margin for pediatric epilepsy surgery objectively. Its primary goal is to minimize surgical risk probability (i.e., functional deficit) and maximize surgical benefit probability (i.e., seizure freedom) by precisely localizing eloquent white matter pathways in children and adolescents with drug-resistant focal epilepsy. This new imaging approach, which will acquire a DWMRI scan before pediatric epilepsy surgery in about 10 minutes without contrast administration (and also without sedation even in young children), can be readily applied to improve preoperative benefit-risk evaluation for pediatric epilepsy surgery in the future. The investigators will also study how the advanced DWMRI-DCNN connectome approach can detect complex signs of brain neuronal reorganization that help improve neurological and cognitive outcomes following pediatric epilepsy surgery. This new imaging approach could benefit targeted interventions in the future to minimize neurocognitive deficits in affected children. All enrolled subjects will undergo advanced brain MRI and neurocognitive evaluation to achieve these goals. The findings of this project will not guide any clinical decision-making or clinical intervention until the studied approach is thoroughly validated.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Multi-Scale Deep Learning of Clinically Acquired Multi-Modal MRI Improves the Localization of Seizure Onset Zone in Children With Drug-Resistant Epilepsy.
Jeong JW, Lee MH, Kuroda N, Sakakura K, et al · · 2022 · cited 18× · PMID 35925854 · DOI 10.1109/jbhi.2022.3196330
Verify or expand the search:
- PubMed search for NCT04986683
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Brain magnetic resonance imaging
Trials testing the same drug.
- NCT04517565 — Longitudinal Neuroimaging in Sturge-Weber Syndrome · NA · active not recruiting
Other recruiting trials for Focal Epilepsy
Currently open trials in the same condition.
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07193277 — Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy · Phase 4 · recruiting
- NCT07139457 — Wearable Epileptic Seizure Prediction and Alert Glasses Based on Neuromorphic Computing · NA · active not recruiting
- NCT06210022 — Cognitive Impairment in Drug-resistant and Drug-responsive Focal Cryptogenic Epilepsy · recruiting
- NCT05981755 — Breathing Rescue for SUDEP Prevention · NA · recruiting
Other Wayne State University trials
Trials by the same sponsor.
- NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
- NCT07123467 — Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder · Phase 3 · recruiting
- NCT07222306 — Cannabis, Neuroinflammation, and Suicidal Ideation: A Supplemental Brain Imaging Study · enrolling by invitation
- NCT05684978 — Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus · Phase 4 · terminated
- NCT06381180 — Warrior CARE: Cannabis Behavioral Health · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04986683 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wayne State University
- Last refreshed: 23 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04986683.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing